CONTINUOUS LISURIDE EFFECTS ON CENTRAL DOPAMINERGIC MECHANISMS IN PARKINSONS-DISEASE

被引:76
|
作者
BARONTI, F [1 ]
MOURADIAN, MM [1 ]
DAVIS, TL [1 ]
GIUFFRA, M [1 ]
BRUGHITTA, G [1 ]
CONANT, KE [1 ]
CHASE, TN [1 ]
机构
[1] NINCDS, EXPTL THERAPEUT BRANCH,BLDG 10,ROOM 5C103, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA
关键词
D O I
10.1002/ana.410320611
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Effects of the long term, continuous administration of a dopamine agonist on motor response complications attending levodopa therapy were studied in 7 patients with advanced Parkinson's disease under controlled conditions. After a 3-month round-the-clock infusion of lisuride, the duration of antiparkinsonian action of levodopa increased by approximately 90%, and the therapeutic window for the acutely administered dopamine precursor widened by >300%. These benefits were more than three times greater than those produced by 9 days of continuous levodopa administration. In contrast to the effects on levodopa pharmacodynamics, the continuous infusion of lisuride did not prolong its action, suggesting a lisuride effect on presynaptic as well as postsynaptic dopaminergic mechanisms. These results lend further support to the view that continuous dopamine replacement ameliorates motor fluctuations and peak-dose dyskinesias that complicate standard levodopa regimens. Our findings further suggest that alterations at both presynaptic and postsynaptic levels contributing to these motor complications tend to normalize with the more physiological stimulation afforded by continuous replacement strategies, especially when given chronically.
引用
收藏
页码:776 / 781
页数:6
相关论文
共 50 条
  • [21] THE DOPAMINE AGONIST LISURIDE IN THE TREATMENT OF PARKINSONS-DISEASE
    MADEJA, UD
    ACTA HISTOCHEMICA, 1992, : 25 - 31
  • [22] THERAPEUTIC EFFECT OF LISURIDE IN ADVANCED PARKINSONS-DISEASE
    MENEGHETTI, G
    BRACCO, F
    GIOMETTO, B
    FERLA, S
    SCHERGNA, E
    EUROPEAN NEUROLOGY, 1986, 25 (01) : 74 - 80
  • [23] FURTHER-STUDIES WITH LISURIDE IN PARKINSONS-DISEASE
    LIEBERMAN, AN
    GOLDSTEIN, M
    GOPINATHAN, G
    LEIBOWITZ, M
    NEOPHYTIDES, A
    WALKER, R
    HIESIGER, E
    EUROPEAN NEUROLOGY, 1983, 22 (02) : 119 - 123
  • [24] DOPAMINERGIC AGONISTS IN PARKINSONS-DISEASE
    KOLLER, WC
    NEUROLOGY, 1993, 43 (02) : 39 - 39
  • [25] TRH TEST AND THE CONTINUOUS DOPAMINERGIC STIMULATION IN COMPLICATED PARKINSONS-DISEASE
    LESTINGI, L
    BONIFATI, V
    STOCCHI, F
    ANTONOZZI, I
    MECO, G
    EUROPEAN NEUROLOGY, 1992, 32 (02) : 65 - 69
  • [26] CENTRAL DOPAMINERGIC RECEPTOR SUPERSENSITIVITY AND ITS RELEVANCE TO PARKINSONS-DISEASE
    PYCOCK, CJ
    MARSDEN, CD
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1977, 31 (01) : 113 - 121
  • [27] LISURIDE PLUS SELEGILINE IN THE TREATMENT OF EARLY PARKINSONS-DISEASE
    NAPPI, G
    MARTIGNONI, E
    HOROWSKI, R
    PACCHETTI, C
    RAINER, E
    BRUGGI, P
    RUNGE, I
    ACTA NEUROLOGICA SCANDINAVICA, 1991, 83 (06): : 407 - 410
  • [28] COMPARISON OF LISURIDE AND BROMOCRIPTINE IN THE TREATMENT OF ADVANCED PARKINSONS-DISEASE
    LAIHINEN, A
    RINNE, UK
    SUCHY, I
    ACTA NEUROLOGICA SCANDINAVICA, 1992, 86 (06): : 593 - 595
  • [29] LISURIDE, A DOPAMINE AGONIST IN THE TREATMENT OF EARLY PARKINSONS-DISEASE
    RINNE, UK
    NEUROLOGY, 1989, 39 (03) : 336 - 339
  • [30] MECHANISMS OF PARKINSONS-DISEASE
    不详
    BRITISH MEDICAL JOURNAL, 1978, 1 (6117): : 872 - 873